 | | Vol. 13.35 – 23 September, 2021 |
| |
|
|
| To optimize the selection of stem cell transplant sources based on the HLA-B leader, an HLA-B Leader Assessment Tool was developed to automate the assignment of leader genotypes, define HLA-B leader match statuses, and rank order candidate stem cell sources according to clinical risk.
[Blood Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the consequences of interaction between placenta MSCs and platelets, and its impact on platelet-mediated atherosclerosis in vitro.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| The possible roles of human umbilical mesenchymal stromal cord and adipose MSCs in neurogenesis and synaptic function were investigated using a β-amyloid 1-42-induced Alzheimer’s disease rat model.
[Heliyon] |
|
|
|
| Human umbilical cord MSC-derived exosome dramatically inhibited T helper cell 2 differentiation, decreased GATA binding protein-3 protein expressions and IL-4 levels by about two times in CD4+ T cells.
[International Archives of Allergy and Immunology] |
|
|
|
| Scientists compared the clinical and radiological results of human umbilical cord-blood derived MSC cartilage regeneration procedures combined with high tibial osteotomy (HTO) to those of microfracture with HTO.
[Knee] |
|
|
|
| The authors analyzed cellular, molecular, and chromosomal alterations in Wharton’s jelly-derived MSCs during their in vitro sequential passages.
[Cells Tissues Organs] |
|
|
|
|
| Investigators provide an overview of humab bone-marrow-MSCs, the application of these cells to various neurological diseases, and improvements in their quality and freshness based on integrated omics after detachment from the culture dish for successful cell therapy.
[Stem Cell International] |
|
|
|
| The authors compile pertinent preclinical Alzheimer’s disease research on transgenic mice as well as clinical trials on MSC-based therapy from diverse sources.
[Stem Cells International] |
|
|
|
|
| The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million.
[Stanford Medicine] |
|
|
|
|
| September 30 – October 1, 2021
Virtual |
|
|
|
|
|
| | NHS Blood and Transplant – Oxford, England, United Kingdom |
|
|
|
| | King Abdullah University of Science and Technology – Thuwal, Saudi Arabia |
|
|
|
| | Broad Institute – Cambridge, Massachusetts, United States |
|
|
|
| | University of Southern California – Los Angeles, California, United States |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
